Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2015-05-07 Earnings Release
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
Version PDF
Earnings Release Classification · 98% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces the company's "CHIFFRE D'AFFAIRES ET SA TRESORERIE AU 31 MARS 2015" (Revenue and Cash Position as of March 31, 2015). This content—key financial highlights for a specific period (Q1 2015)—is the definition of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of period results. Q1 2015
2015-05-07 French
PDF Version
Earnings Release Classification · 98% confidence The document is explicitly titled "GENFIT ANNOUNCES ITS TURNOVER AND CASH SITUATION AS OF MARCH 31, 2015" and provides key financial figures (turnover and cash position) for the first quarter of 2015. This content structure—a brief announcement highlighting key financial metrics for a specific interim period (Q1)—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). Since it announces the results rather than just announcing the publication of a report, ER is the most appropriate classification. Q1 2015
2015-05-07 English
PDF Version
AGM Information Classification · 95% confidence The document is explicitly titled as a "Press release" announcing the "AVAILABILITY OF PREPARATORY DOCUMENTS" for the "ORDINARY GENERAL SHAREHOLDERS' MEETING OF JUNE 3, 2015". It details where shareholders can access the required documentation for the upcoming AGM, rather than being the AGM presentation itself (AGM-R) or the official voting results (DVA). Since it is an announcement about the availability of materials related to a general meeting, it functions as a notice or regulatory communication. Given the options, this announcement is most closely related to the materials distributed for the AGM, but the document itself is a press release announcing the availability of those materials. The closest fit for an announcement related to the AGM process, especially concerning the availability of documents required for the meeting, is often captured under general regulatory announcements or specific AGM-related filings. However, since the core subject is the preparation for the AGM, and it is a press release format, it is best classified as an announcement related to the AGM process. If the content were the actual presentation slides, it would be AGM-R. Since it is a notice about the availability of preparatory documents for the AGM, it fits best under AGM-R as it directly pertains to the meeting's preparatory phase, or potentially RPA/RNS if interpreted strictly as a report publication announcement. Given the strong focus on the 'Ordinary General Shareholders' Meeting', AGM-R is the most contextually relevant choice, as it signals information directly preceding or concerning the AGM event itself, even if it's just the availability notice.
2015-05-07 English
Version PDF
Earnings Release Classification · 95% confidence The document is explicitly titled "Communiqué de presse" (Press Release) dated April 24, 2015. It details the content of presentations given to investors and analysts regarding clinical trial results (GOLDEN-505 study for NASH treatment GFT505) and announces the plan for Phase 3 development. This format—a formal announcement summarizing key findings and future plans, often released to the public and media—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, the best fit among the provided options is 'ER' (Earnings Release), as it communicates key financial/clinical performance highlights and outlook to the market, even though it's not strictly quarterly earnings. Given the context of presenting study results and development plans to investors, it functions as a major corporate update release. FY 2015
2015-04-24 French
PDF Version
Earnings Release Classification · 95% confidence The document is explicitly labeled as a "Press release" from 2015. It details the content of presentations given at an analyst and investor event regarding the drug GFT505, including efficacy data, study results (GOLDEN-505), and the Phase 3 development plan. This content—summarizing recent results and strategic updates for investors and analysts—is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP). Since it is a press release announcing key findings and strategic direction following a study update, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial/study results and key highlights, even though it's not strictly quarterly financial results. It is too detailed for a simple Report Publication Announcement (RPA) and is not a full transcript (CT) or a formal regulatory filing like a 10-K or IR. Given the focus on study results and future plans presented to investors, ER is the most appropriate fit among the options. FY 2015
2015-04-24 English
PDF Version
Earnings Release Classification · 95% confidence The document is a press release titled 'GENFIT: ANNUAL RESULTS FOR 2014'. It provides a summary of financial highlights, major achievements, and business updates for the fiscal year 2014. While it contains some financial data, it is structured as a press release (indicated by the 'Press release' header and contact information) and explicitly directs readers to the company website for the full consolidated financial statements. Therefore, it is an Earnings Release (ER) rather than a full Annual Report (10-K) or Interim Report (IR). FY 2014
2015-04-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.